tert-butyl 4-(5-bromo-3-fluoropyridin-2-yl)piperazine-1-carboxylate | 1289048-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(5-bromo-3-fluoropyridin-2-yl)piperazine-1-carboxylate
• CAS: 1289048-68-5
• 化学式: C₁₄H₁₉BrFN₃O₂
• 分子量: 360.226
• InChiKey: BOJKKHQWWKIHGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-bromo-3-fluoropyridin-2-yl)piperazine-1-carboxylate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 甲基磺酰胺 、 AD-mix α 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 水 、 叔丁醇 为溶剂， 反应 18.5h， 生成 tert-butyl 4-(5-((1S,2S)-1,2-dihydroxypropyl)-3-fluoropyridin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF
  [FR] ANTAGONISTES DE TRPV1 COMPRENANT UN SUBSTITUANT DIHYDROXY ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2012176061A9
• 作为产物：
  描述：

  2-氯-3-氟-5-溴吡啶 、 N-Boc-哌嗪 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以28%的产率得到tert-butyl 4-(5-bromo-3-fluoropyridin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A

文献信息

• [EN] 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(PYRAZOLYL)-1H-PYRROLO[2,3-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014006554A1

  公开（公告）日：2014-01-09

  The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

  本申请涉及一种新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物，其化学式为(I)，作为蛋白激酶抑制剂。该发明特别涉及化合物的化学式(I)、化合物的制备以及其药物组成。该发明还涉及药用可接受的盐和组合物，包括所述新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物及其在治疗各种疾病中的应用。
• [EN] COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ ANTAGONISTE DES TRPV1 ET LEURS UTILISATIONS
  申请人：SHIONOGI & CO

  公开号：WO2011162409A1

  公开（公告）日：2011-12-29

  The invention relates to compounds of Formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

  该发明涉及化合物I的公式和其药用可接受的衍生物，包含有效量的化合物I或其药用可接受的衍生物的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要的动物施用化合物I或其药用可接受的衍生物的有效量。
• [EN] BRAF DEGRADERS<br/>[FR] AGENTS DE DÉGRADATION DE BRAF
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021255212A1

  公开（公告）日：2021-12-23

  Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

  本发明提供了能够特异性降解BRAF的化合物。这些化合物可用于治疗各种癌症。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF
  申请人：Ando Shigeru

  公开号：US20140329829A1

  公开（公告）日：2014-11-06

  The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R 1 , R 4 , R 8 , R 9 , and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.

  本公开涉及化合物公式(I)及其药学上可接受的衍生物，其中R1，R4，R8，R9和m的定义如本文所述，包括含有化合物公式(I)或其药学上可接受的衍生物的有效量的组合物，以及用于治疗或预防疼痛、与骨关节炎相关的疼痛、骨关节炎、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物中施用化合物公式(I)或其药学上可接受的衍生物的有效量。